by jmanor | Jun 7, 2023 | White Papers
Historically, Medicare has reimbursed drugs approved by the Food and Drug Administration (FDA) including drugs granted accelerated approval. In 2021, FDA granted accelerated approval to plaque-targeting treatments for Alzheimer’s disease (AD), but the Centers for...
by susuguo | May 2, 2023 | Journal, White Papers
The extent of voluntary cooperation in the presence of externalities is shown as an equilib- rium outcome in the supply and demand framework. The analysis uses familiar ingredients to provide a new way of understanding the results of the extensive literature beginning...
by jmanor | Apr 3, 2023 | White Papers
The Biden administration has made reducing health disparities a major goal of its health care agenda. This paper provides analysis of whether and how biopharmaceutical innovation has historically reduced disparities in health outcomes and how reducing such innovation...
by jmanor | Feb 15, 2023 | White Papers
This paper provides the first quantitative economic models of pharmacy benefit management (PBM) regulation. Indeed, few economic models of the pharmaceutical industry even acknowledge that drug benefits are managed and that companies specialize in benefit management....
by jmanor | Nov 29, 2022 | White Papers
Despite the large disease burden imposed by Alzheimer’s disease (AD), little quantitative evidence exists on the aggregate value stemming from innovation slowing the progression of the disease. To fill this gap, this paper uses the existing evidence base to assess the...
by jmanor | Aug 12, 2022 | White Papers
A longstanding economic literature argues that the total welfare loss of a disease comes not only from the direct effects of the disease itself, but also the costs of preventing the disease. This paper assesses how new medical innovations for COVID-19—specifically...